Core Viewpoint - The China Securities Hong Kong Biotechnology Theme Index has shown significant growth, with a year-to-date increase of 41.25% [1] Group 1: Index Performance - The China Securities Hong Kong Biotechnology Theme Index reported a value of 1436.15 points, with a monthly increase of 5.87% and a three-month increase of 12.26% [1] - The index is composed of 50 listed companies in Hong Kong involved in biopharmaceuticals, pharmaceuticals, and biotechnology services, reflecting the overall performance of these companies [1] Group 2: Index Composition - The top ten weighted companies in the index are: BeiGene (14.97%), WuXi Biologics (11.09%), Innovent Biologics (10.93%), CanSino Biologics (6.86%), CSPC Pharmaceutical Group (6.41%), China Biologic Products (5.46%), 3SBio (4.21%), Hansoh Pharmaceutical (3.59%), Zai Lab (2.97%), and WuXi AppTec (2.93%) [1] - The index is fully composed of companies listed on the Hong Kong Stock Exchange, with a 100% allocation [1] Group 3: Industry Breakdown - The industry composition of the index shows that biopharmaceuticals account for 53.76%, chemical drugs for 24.57%, pharmaceutical and biotechnology services for 18.50%, and medical devices for 3.18% [2] - The index samples are adjusted biannually, with adjustments occurring on the next trading day after the second Friday of June and December [2]
中证香港生物科技主题指数报1436.15点，前十大权重包含三生制药等